chevron_leftBack
As of 17 June 2026, JW Shinyak Corp. has a market cap of $75.44M USD, ranking #27624 globally and #1426 in South Korea.
It ranks #2492 in the Healthcare sector, and #896 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$75.44MUSD
114.26B KRW
Enterprise Value
$77.47MUSD
117.6B KRW
Revenue (TTM)
$53.51MUSD
81.04B KRW
EBITDA (TTM)
$6.08MUSD
9.23B KRW
Net Income (TTM)
$10.34MUSD
15.66B KRW
EBITDA Margin
11%
Profit Margin
19%
PE Ratio
8.3
PS Ratio
1.4
PB Ratio
2.8
EV/EBITDA
12.7
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Yong-Kwan Kim
open_in_new
Employees
183
Founded
1981
Website
jw-shinyak.co.kr
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.2% | 3.2% | 3.5% | 2.2% | 52% | 41% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
067290
제이더블유신약(주)
ISIN: KR7067290007
Shares Out.:
Shares Outstanding:
55.881M1
Shares Float:
38.522M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
2,045 KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About JW Shinyak Corp.
JW Shinyak Corporation engages in the research, development, production, and sale of medicines and medical supplies in South Korea. It offers pharmaceutical products in the areas of dermatology, urology, pediatrics, otolaryngology, etc.; and cardiovascular, gastrointestinal, urinary, NSAIDs, antibiotics, anti-fungal, anti-viral, respiratory, antihistamines, steroid hormone, anti-obesity, and other products, as well as eye drops, and antitussives and expectorants. The company also develops prostate cancer treatment, liver cancer treatment, rheumatoid arthritis treatment, etc. using immune cells. JW Shinyak Corporation was founded in 1981 and is headquartered in Gwacheon-si, South Korea.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
KRX: 0126Z0
|
$9.18B
12K%
13.91T KRW
|
-
|
|
KRX: 000250
|
$6.8B
9K%
10.3T KRW
|
1958.1
|
|
KRX: 326030
|
$5.26B
7K%
7.97T KRW
|
29.9
|
|
KRX: 298380
|
$4.98B
7K%
7.55T KRW
|
-
|
|
KRX: 000100
|
$4.57B
6K%
6.92T KRW
|
35.9
|
|
KRX: 141080
|
$4.46B
6K%
6.76T KRW
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
1M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
725K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
478K%
|
97.4
|
|
SIX: RO
|
$322.73B
428K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$289.3B
383K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$275.68B
365K%
218.9B CHF
|
20.5
|
chevron_leftBack